Company intelligence / Profile preview

Recombinant Technologies

Cheshire, Connecticut, United Statesrecombtech.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Successful proof-of-concept studies for AmyTrap drug candidates have shown ability to trap and clear Alzheimer's disease-causing Aβ-amyloid plaques, restoring memory by returning the natural balance of beta-amyloid in the body. The company has received Phase II SBIR grant from NIH to further develop AmyTrap for Alzheimer's treatment[7].

Therapeutic areas: Neurology
Modalities: Small moleculespeptides
Industry: Biotech

Drug pipeline

4 assets

AmyTrap 2

Preclinical

3 more assets in the full pipeline.

Request access →

Partnerships

Health ConnexionsSA Capital Partners LLC

Beyond the preview

Go deeper on Recombinant Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Recombinant Technologies.

Explore the full profile